7 Articles found

Nanostics Inc. articles

Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer

Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries.
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant p

Aug. 23, 2022

Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer

Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate^® is 147% more specific than the PSA test for predicting clinically significant prostate cancer.
Using ClarityDX Prostate^® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies.
The clinical study recruited men from two sites in Alberta, Canada, and one site in Baltimore, USA

Jul. 30, 2022

Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer

Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Canc

Jul. 20, 2022

Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site

Summary

Nanostics` clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions
A top-ranked research institute in the Northeast US will now partner with Nanostics` by recruiting patients for the clinical validation study
This partnership will significantly accelerate the

Jun. 16, 2020

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients

Edmonton, Alberta - Nanostics Inc., a diagnostic healthcare company that focuses on developing tests to determine a patient`s disease risk, announced today plans to develop and validate ClarityDX COVID-19; a simple blood test to predict the severity of COVID-19 disease in patients.

Nanostics, in collaboration with the Canadian BioSample Repository (CBSR) at the University of Alberta and Century Clinical Research Institute (CCRI), a Florida based clinical research company experienced a

Apr. 20, 2020